New drug targets hard-to-treat cancers in early trial

NCT ID NCT07631884

Not yet recruiting Disease control Sponsor: Haihua Yuan Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract neoplasm Biliary Tract Neoplasms cancer colorectal neoplasm endometrium neoplasm gastric neoplasm head and neck neoplasm Head and Neck Neoplasms metastatic malignant neoplasm neoplasm Neoplasm Metastasis non-small cell lung carcinoma pancreatic neoplasm transitional cell carcinoma urothelial carcinoma Uterine Cervical Neoplasms uterine cervix neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANT SOLID NEOPLASM BILIARY TRACT NEOPLASMS CERVICAL NEOPLASMS COLORECTAL NEOPLASMS ENDOMETRIAL NEOPLASMS GASTRIC NEOPLASMS HEAD AND NECK NEOPLASMS HER2 EXPRESSION LOCALLY ADVANCED MALIGNANT SOLID NEOPLASM METASTATIC MALIGNANT SOLID NEOPLASM NEOPLASMS (CANCER / TUMORS) NON SMALL CELL LUNG CARCINOMA NSCLC PANCREATIC NEOPLASMS SOLID TUMORS UNRESECTABLE MALIGNANT SOLID NEOPLASM UROTHELIAL CARCINOMA (UC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.